Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

Background Since initial approval for the treatment of rheumatoid arthritis (RA), rituximab has been evaluated in clinical trials involving various populations with RA. Information has also been gathered from registries. This report therefore updates the 2007 consensus document on the use of rituximab in the treatment of RA. Methods Preparation of this new document involved many international experts experienced in the treatment of RA. Following a meeting to agree upon the core agenda, a systematic literature review was undertaken to identify all relevant data. Data were then interrogated by a drafting committee, with subsequent review and discussion by a wider expert committee leading to the formulation of an updated consensus statement. These committees also included patients with RA. Results The new statement covers wide-ranging issues including the use of rituximab in earlier RA and impact on structural progression, and aspects particularly pertinent to rituximab such as co-medication, optimal dosage regimens, repeat treatment cycles and how to manage non-response. Biological therapy following rituximab usage is also addressed, and safety concerns including appropriate screening for hepatitis, immunoglobulin levels and infection risk. This consensus statement will support clinicians and inform patients when using B-cell depletion in the management of RA, providing up-to-date information and highlighting areas for further research. Conclusion New therapeutic strategies and treatment options for RA, a chronic destructive and disabling disease, have expanded over recent years. These have been summarised in general strategic suggestions and specific management recommendations, emphasising the importance of expedient disease-modifying antirheumatic drug implementation and tight disease control. This consensus statement is in line with these fundamental principles of management

Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis

Variation in body iron is associated with or causes diseases, including anaemia and iron overload. Here, we analyse genetic association data on biochemical markers of iron status from 11 European-population studies, with replication in eight additional cohorts (total up to 48,972 subjects). We find 11 genome-wide-significant (P<5 × 10(-8)) loci, some including known iron-related genes (HFE, SLC40A1, TF, TFR2, TFRC, TMPRSS6) and others novel (ABO, ARNTL, FADS2, NAT2, TEX14). SNPs at ARNTL, TF, and TFR2 affect iron markers in HFE C282Y homozygotes at risk for hemochromatosis. There is substantial overlap between our iron loci and loci affecting erythrocyte and lipid phenotypes. These results will facilitate investigation of the roles of iron in disease

Correction: Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial

BACKGROUND: Acute exacerbations contribute to the morbidity and mortality associated with chronic obstructive pulmonary disease (COPD). This proof-of-concept study evaluates whether intermittent pulsed moxifloxacin treatment could reduce the frequency of these exacerbations. METHODS: Stable patients with COPD were randomized in a double-blind, placebo-controlled trial to receive moxifloxacin 400 mg PO once daily (N = 573) or placebo (N = 584) once a day for 5 days. Treatment was repeated every 8 weeks for a total of six courses. Patients were repeatedly assessed clinically and microbiologically during the 48-week treatment period, and for a further 24 weeks' follow-up. RESULTS: At 48 weeks the odds ratio (OR) for suffering an exacerbation favoured moxifloxacin: per-protocol (PP) population (N = 738, OR 0.75, 95% confidence interval (CI) 0.565-0.994, p = 0.046), intent-to-treat (ITT) population (N = 1149, OR 0.81, 95% CI 0.645-1.008, p = 0.059), and a post-hoc analysis of per-protocol (PP) patients with purulent/mucopurulent sputum production at baseline (N = 323, OR 0.55, 95% CI 0.36-0.84, p = 0.006).There were no significant differences between moxifloxacin and placebo in any pre-specified efficacy subgroup analyses or in hospitalization rates, mortality rates, lung function or changes in St George's Respiratory Questionnaire (SGRQ) total scores. There was, however, a significant difference in favour of moxifloxacin in the SGRQ symptom domain (ITT: -8.2 vs -3.8, p = 0.009; PP: -8.8 vs -4.4, p = 0.006). Moxifloxacin treatment was not associated with consistent changes in moxifloxacin susceptibility. There were more treatment-emergent, drug related adverse events with moxifloxacin vs placebo (p < 0.001) largely due to gastrointestinal events (4.7% vs 0.7%). CONCLUSIONS: Intermittent pulsed therapy with moxifloxacin reduced the odds of exacerbation by 20% in the ITT population, by 25% among the PP population and by 45% in PP patients with purulent/mucopurulent sputum at baseline. There were no unexpected adverse events and there was no evidence of resistance development. TRIAL REGISTRATION: ClinicalTrials.gov number, NCT00473460 (ClincalTrials.gov)

Adaptabilidade, estabilidade e resistência a patógenos em genótipos de feijoeiro

Resumo:O objetivo deste trabalho foi avaliar a resistência de genótipos de feijoeiro aos principais patógenos da cultura, bem como a adaptabilidade e a estabilidade de produção de grãos desses genótipos. Avaliaram-se 26 genótipos de feijoeiro quanto à resistência a Colletotrichum lindemuthianum, Fusarium oxysporum f. sp. phaseolie Xanthomonas axonopodis pv. phaseoli, por meio de inoculação, em laboratório, e em 19 ensaios de valor de cultivo e uso (VCU), em diferentes locais do Estado de São Paulo, nas safras das "águas", "seca" e "inverno", durante os anos agrícolas 2011, 2012 e 2013. Dezoito genótipos foram considerados resistentes: sete deles a C. lindemuthianum, sete a F. oxysporumf. sp. phaseolie quatro a X. axonopodispv. phaseoli. A reação de resistência aos patógenos está associada à estabilidade dos genótipos. Por meio das análises GGE biplot, foi possível identificar genótipos com adaptabilidade e estabilidade superiores às das testemunhas, nos dois grupos de tegumento avaliados, em todas as épocas de semeadura

Parâmetros genéticos e análise de trilha para o florescimento precoce e características agronômicas da alface

O objetivo deste trabalho foi avaliar os parâmetros genéticos das características agronômicas e de tolerância ao florescimento precoce de onze cultivares de alface, bem como verificar a existência de associação entre as características. O experimento foi realizado em ambiente protegido, em delineamento de blocos ao acaso, com quatro repetições e doze plantas por parcela. Quarenta e cinco dias após o transplantio das mudas, foram mensuradas as seguintes características: massa de matéria fresca total e "comercial" da parte aérea, massa de matéria seca "comercial" da parte aérea, massa de matéria fresca e seca da raiz, diâmetro e circunferência da cabeça, altura de planta, número de folhas por planta e número de dias até a antese. Há variabilidade genética entre as cultivares, em todas as variáveis, exceto quanto à circunferência de planta e matéria fresca da raiz. As cultivares Regina 500, Lívia e Atração foram superiores quanto ao número de dias para o florescimento e também para as demais características avaliadas. A seleção contra o florescimento precoce ocasionou ganho em todas as características; porém, não interferiu na matéria seca da raiz. A matéria fresca da parte aérea e o diâmetro de cabeça são indicadas para a seleção indireta contra o florescimento precoce